503b semaglutide The FDA has proposed to bar outsourcing facilities from bulk compounding and tirzepatide. The shortage-list pathway already closed in 2024 and 2025; this proposal would remove the remaining bulks-list route A War Brewing' Between GLP-1

Other fermented foods can help as well

The company's materials describe this program as involving the same active ingredient associated with branded medications Ozempic and Wegovy

The program is designed to meet regulatory requirements in specific states

The SUSTAIN 6 clinical trial, sponsored by Novo Nordisk, explores cardiovascular outcomes for patients taking Semaglutide injections at doses as low as 0.5mg

Clinical Evidence for GLP-1 Therapy in Midlife Weight Management A 2023 randomized trial in the Journal of Clinical Endocrinology & Metabolism found that women over 50 on GLP-1 therapy lost an average of 12-15% of baseline body weight over 52 weeks, with superior metabolic improvements compared to younger populations

Study 1: Nutrient Intake on GLP-1 Receptor Agonists A cross-sectional study published in Frontiers in Nutrition (April 2025) examined 69 adults who had been using a GLP-1 receptor agonist for at least one month